Characteristics and outcomes of anti-mycobacterial therapy compared to no anti-mycobacterial therapy for NTM pulmonary disease

•Fibronodular bronchiectatic NTM-PD treated with anti-mycobacterial therapy have a higher rate of sputum conversion.•Patients not receiving anti-mycobacterial therapy were equally as likely to be asymptomatic at follow-up.•Further studies are needed to clarify the impact of airway clearance regimens and evaluate longer-term follow-up.